File(s) under permanent embargo
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
journal contribution
posted on 2012-12-01, 00:00 authored by J Ni, P Cozzi, Wei DuanWei Duan, Sarah ShigdarSarah Shigdar, P Graham, K John, Y LiDespite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a transmembrane glycoprotein that is highly expressed in rapidly proliferating carcinomas and plays an important role in the prevention of cell–cell adhesion, cell signalling, migration, proliferation and differentiation. Stably and highly expressed EpCAM has been found in primary CaP tissues, effusions and CaP metastases, making it an ideal candidate of tumour-associated antigen to detect metastasis of CaP cells in the circulation as well as a promising therapeutic target to control metastatic CRPC disease. In this review, we discuss the implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP. We also summarize EpCAM expression in human CaP and EpCAM-mediated signalling pathways in cancer metastasis. Finally, emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications of EpCAM for targeted strategies in future CaP therapy will be explored.
History
Journal
Cancer metastasis reviewsVolume
31Issue
3-4Pagination
779 - 791Publisher
Springer New York LLCLocation
New York, N. Y.Publisher DOI
ISSN
0167-7659eISSN
1573-7233Language
engPublication classification
C1 Refereed article in a scholarly journalUsage metrics
Categories
No categories selectedKeywords
EpCAMprostate cancerimmunotherapyprognosiscirculating tumour cellstargeted cancer therapyScience & TechnologyLife Sciences & BiomedicineOncologyCIRCULATING TUMOR-CELLSENGINEERED(TM) MONOCLONAL-ANTIBODYPOTENTIAL THERAPEUTIC TARGETSEP-CAM EXPRESSIONBREAST-CANCERADHESION MOLECULEMALIGNANT ASCITESBISPECIFIC ANTIBODYSTEM-CELLSPREDICT SURVIVAL
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC